Stay updated with breaking news from Be Limited. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Hyderabad-based pharmaceutical and vaccine manufacturer Biological E Limited (BE), on Friday announced that its 14-valent paediatric Pneumococcal Conjugate Vaccine has received approval for manufacture and commercialisation in India.
Get latest articles and stories on India at LatestLY. Streptococcus pneumonia infection remains one of the leading causes of death among children under five in India and developing countries. BE's PCV14 Vaccine will help prevent invasive pneumococcal infection and save millions of lives worldwide. PCV14 may be administered to infants of 6, 10 and 14 weeks of age, Biological E said. India News | Biological E Gets DCGI's Nod to Manufacture, Market 14-valent Pneumococcal Conjugate Vaccine.
Biological E. Limited (BE), a Hyderabad-based Pharmaceutical and Vaccine Company Friday announced that its 14-valent paediatric Pneumococcal Conjugate Vaccine, (Investigational Pneumococcal Polysaccharide Conjugate Vaccine PCV14) against S. ...
Hyderabad:Biological E. Limited (BE), the Hyderabad-based vaccine's manufacturer, announced today that the Subject Expert Committee of CDSCO reviewed and approved the Phase 3 infants clinical trial data and recommended for the manufacture of its 14-valent pediatric vaccine (investigational pneumococcal polysaccharide conjugate vaccine PCV14) against S. pneumonia infection in
Vaccine manufacturer Biological E. Limited (BE) announced on Thursday that the Subject Expert Committee of Central Drugs Standard Control Organization (CDSCO) has approved the Phase 3 infants clinical trial data and recommended for manufacture ...